
Isomorphic Labs raises $5 billion to advance AI drug programs
Isomorphic Labs raised a $5 billion Series C co-led by Greenoaks and Sequoia, pushing AI-designed therapies toward trials while leaving its valuation undisclosed.
- By
- Sophie Lindqvist
- Filed
- Channel
- Startups & Funding
- Read
- 4 min read
By Sophie Lindqvist
Isomorphic Labs raised a $5 billion Series C on Tuesday, Nov. 17 to advance its first therapeutic programs toward clinical trials. Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and several other new investors participated, while Alphabet and every existing investor also took part.
Who backed the round?
Existing investors include Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic described Alphabet’s participation as continued significant investment. The named investor roster does not indicate how much each participant committed, what governance rights it received, or how the $5 billion divides among research, platform development and clinical development infrastructure.
The round arrived six months after Isomorphic raised $2.1 billion in a Series B led by Thrive in May. It followed a $600 million first external round in March 2025. Isomorphic had spun out of Google DeepMind in 2021.
Isomorphic did not disclose a valuation. Bloomberg reported on Nov. 4, citing unnamed sources, that the company was in talks to raise $5 billion at about a $50 billion valuation. The $50 billion figure came from reported negotiations, not a company-confirmed valuation.
What will the capital advance?
Isomorphic builds on software developed at DeepMind, including AlphaFold, the Nobel Prize-winning model that predicts protein structures. The company is scaling its proprietary drug-design engine, IsoDDE, and a pipeline of therapeutic candidates designed with AI.
Tech.eu reported that Isomorphic researches treatments for cancer and immune disorders. It said the new money will support AI development and clinical development infrastructure as candidates move toward trials. The announcement specified no candidate count, trial phase or clinical budget, so investors cannot yet translate the funding scale into expected trial capacity or comparative development speed.
“This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” Hassabis said.
The statement defines acceleration through models, disease understanding and trial entry, but offers no candidate-level data or efficacy threshold against which investors could measure that promised progress.
When will the first trial begin?
Isomorphic says on its website that its lead internal programs are advancing toward the clinic. Hassabis has said he expects the first clinical trials to start by the end of 2026. Tech Funding News reported that this target had already slipped once, from 2025.
Isomorphic did not identify the first molecule, disease indication or trial site. Its end-2026 target remains a management forecast rather than a scheduled study, and the prior slip from 2025 adds execution risk.
Isomorphic also works with drugmakers. In January 2024, the company signed deals with Eli Lilly worth up to $1.7 billion in milestone payments and Novartis worth up to $1.2 billion. Johnson & Johnson joined as a partner in January 2026 on undisclosed terms. Those figures describe potential milestone value, not guaranteed revenue or clinical success.
What changed in Hassabis’s role?
Hassabis has served as Isomorphic’s CEO since its founding. On Aug. 5, he stepped down as Google DeepMind CEO and became the unit’s chairman and Alphabet’s chief scientist. DeepMind CTO Koray Kavukcuoglu assumed day-to-day management as senior vice president.
Hassabis said at the time that he would spend more time at Isomorphic. The arrangement reduces his day-to-day DeepMind responsibilities while placing greater emphasis on the drug company, but the announcement gives no schedule for that allocation or details of any governance change.
Alphabet’s continued significant investment confirms its financial backing. The Series C disclosed no valuation, however, so Alphabet’s stake size and the economics of its position remain unavailable.
How large is the AI-drug funding wave?
Investors have put record sums into AI drug discovery in 2026. Drug-discovery startups raised $23.2 billion during the year, a record according to Dealroom data cited by CNBC.
The $23.2 billion total covers a startup cohort whose boundaries the cited report does not define, whereas Isomorphic’s $5 billion covers one company alone, with a much narrower funding scope. Both figures show how large private funding has become.
OpenAI and Anthropic also broadened the competitive field around partnerships and capital. OpenAI partnered with Novo Nordisk in April, and Anthropic launched an AI drug-discovery program in June. The report provides no candidate counts, trial schedules or capital commitments for either effort, so entry alone does not establish a clinical lead.
Isomorphic’s next verifiable milestone is the first clinical trial starting by the end of 2026, even as OpenAI and Anthropic expand the competitive field during a record $23.2 billion funding year.
Source: mlq.ai
More from Sophie Lindqvist
Show full bio
News editor covering money, funding and market shifts around Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.
1,086 articles
Related articles
seven-billionaire-led-startups-raised-more-than-260-billion
Seven Billionaire-Led Startups Raised More Than $260 Billion
deepseeks-15-9b-round-lifts-october-venture-funding-to-59b
DeepSeek’s $15.9B Round Lifts October Venture Funding to $59B

